Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G., Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease, «DRUGS IN CONTEXT», 2022, 11, Article number: A1 , pp. 1 - 10 [Scientific article]
De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G., Advanced non-small-cell lung cancer: how to manage non-oncogene disease, «DRUGS IN CONTEXT», 2022, 11, Article number: 2022-2-4 , pp. 1 - 14 [Scientific article]Open Access
Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G., Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 361 - 369 [Scientific article]
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi, Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?, «FUTURE ONCOLOGY», 2022, 905, pp. 1 - 12 [Scientific article]
Di Federico, Alessandro; Filetti, Marco; Palladini, Arianna; Giusti, Raffaele; Piras, Marta; De Giglio, Andrea; Ardizzoni, Andrea; Gelsomino, Francesco, EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature, «TRANSLATIONAL LUNG CANCER RESEARCH», 2022, 11, pp. 497 - 503 [Scientific article]Open Access
De Giglio A.; Di Federico A.; Metro G., Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer, «TRANSLATIONAL LUNG CANCER RESEARCH», 2022, 11, pp. 1734 - 1738 [Scientific article]
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes, «CANCERS», 2022, 14, Article number: 3472 , pp. 1 - 15 [Scientific article]Open Access
Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F., Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies, «IMMUNOTHERAPY», 2022, 14, pp. 1329 - 1340 [Scientific article]
Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429 , pp. 1 - 14 [Scientific article]Open Access
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429 , pp. 1 - 14 [Scientific article]Open Access
De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea, Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC), «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2022, 23, pp. 10292 - 10299 [Scientific article]Open Access
Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 371 - 378 [Scientific article]
Rossi, Simone; Merli, Elena; Rinaldi, Rita; Deleonardi, Gaia; Mastrangelo, Vincenzo; Sasdelli, Anna Simona; Di Federico, Alessandro; Guarino, Maria; Donadio, Vincenzo; Pironi, Loris; Gelsomino, Francesco; De Giorgio, Roberto; D'Angelo, Roberto, Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review, «JOURNAL OF NEUROLOGY», 2022, 269, pp. 1182 - 1194 [Scientific article]
De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chiocchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco, Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience, «LUNG CANCER», 2022, 174, pp. 91 - 96 [Scientific article]
De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea, The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy, «CANCERS», 2022, 14, pp. 5845 - 5851 [Scientific article]Open Access
